Plum Bio Issued Shares To Purchase Assets Continues Suspension Announcement

Securities Code: 600873 Securities Short: Plum Biological Announcement No.: 2016-004cP4Meihua Biotech Group Co., LtdcP4issued shares to purchase assets continued to be suspended notice
cP4the board of directors and all directors to ensure that the contents of this announcement are free of any false records, misleading statements or material omissions, and to bear individual and joint liability for the authenticity, accuracy and completeness of the contents of this announcementcP4
The shares of Meihua Biotech Group Co., Ltd(hereinafter referred to as the Company or Plum Bio) were suspended on December 17, 2015 upon application by the Company in the event that they were planning to issue shares to purchase assetsAfter argumentation and consultation with the parties concerned, the above-mentioned matters do not constitute a major asset restructuringOn December 24, 2015, the Company issued the "Announcement of Suspension of Trading in the Issue of Shares of Meihua Biotech Group Co., Ltd."cP4
1Restructuring Framework Introduces the main trading purposes of cP4 (i) and the cP4 In order to further improve the asset quality, financial position, enhance core competitiveness and continuous operation ability of Meihua Bio, Meihua Bio intends to purchase the assets held in China by issuing shares, and the controlling shareholder stake of the company, Meng Qingshan and Meihua Bio-Related Shareholders, to transfer their shares to Xijie Upon completion of the transaction, Hijwill will become the largest shareholder of Plum Bio, directly or indirectly Upon completion of this transaction, there may be a change in the actual controller of plum bio cP4
　　The counterparty, Hi-Jie, is a joint-stock company established under Korean law and listed on the Korea Exchange, stock code: 097950 Ks cP4
　　(2) Trading Plan cP4 1 New shares issued: Meihua Bio issues shares to Hi-Jie to purchase its amino acid fermentation assets and its supporting assets in China cP4
　　2 Transfer of Old Shares: The shares of Meng Qingshan and Meihua Bio-related shareholders shall transfer part of The Shares of Meihua Bio to the other parties designated by Hij or Hija cP4
　　3 The transfer of old shares and the issuance of new shares are mutual prerequisites cP4
　　(3) The underlying assets cP4 the assets to be purchased by the company in the company's proposed shares are the amino acid fermentation assets and their supporting assets legally owned by Shijie in China, and the assets of the above-mentioned assets belong to the same manufacturing-food manufacturing industry as listed companies (the industry classification of listed companies is determined by reference to the "Industry Classification Results of Listed Companies in the 2q Quarter of 2015" published on the website of the China Association of Listed Companies) cP4
　　2 Progress of the reorganization cP4 (I) On January 11, 2016, Meng Qingshan, the controlling shareholder of the Company, and The Counterparty Xijie signed part of the non-legally binding framework agreement on restructuring, namely, the framework agreement between Xijie First Sugar Co., Ltd and Meng Qingshan on the restructuring of Meihua Biotech Group Co., Ltd cP4
　　(2) The company is, in accordance with the relevant provisions, organizing relevant intermediaries to conduct audits, assessments, legal and financial advisory services on the assets of the subject cP4
　　3 The reasons for the failure to resume trading on schedule cP4 since the suspension of trading, the company and the parties concerned have actively promoted the issue of shares to purchase assets due diligence, audit, evaluation and business negotiations and other work At present, the company is working closely to organize audit institutions, evaluation agencies to carry out audits and assessments of the assets of the target, independent financial advisers and legal advisers are carrying out due diligence work At the same time, the transaction related parties on the specific matters of this transaction plan need to continue in-depth consultation, so the Company can not as originally planned by January 24, 2016 to disclose the issuance of shares to purchase assets plan or report and re-brand cP4
　　4 Applying for a further suspension of trading time cP4 , upon application, the company's shares from January 25, 2016 onwards to continue to suspend trading for no more than 30 days cP4
　　During the suspension period, the Company and relevant parties will accelerate the process of this transaction, and will promptly fulfill the obligation of information disclosure in accordance with the progress, issue a progress announcement on the relevant matters every five trading days, pending the completion of the relevant work to convene the board of directors to consider the plan or report, timely announcement and re-listing cP4
　　The Company designated the information disclosure media as the Shanghai Securities News and the Shanghai Stock Exchange website (), the relevant announcements are based on the information published in the above-mentioned designated media, please the majority of investors pay attention to the follow-up announcement, pay attention to investment risks cP4
　　This announcement is hereby made cP4
　　The Board of Directors of Meihua Biotech Group Co., Ltd cP4 , January 22, 2016 cP4 Securities Code: 600873 Securities Short: Meihua Bio announcement number: 2016-004 cP4 Meihua Biotech Group Co., Ltd cP4 issued shares to purchase assets continue to be suspended
cP4 the board of directors and all directors to ensure that the contents of this announcement are free of any false records, misleading statements or material omissions, and to bear individual and joint liability for the authenticity, accuracy and completeness of its contents cP4
　　The shares of Meihua Biotech Group Co., Ltd (hereinafter referred to as the Company or Plum Bio) were suspended on December 17, 2015 upon application by the Company in the event that they were planning to issue shares to purchase assets After argumentation and consultation with the parties concerned, the above-mentioned matters do not constitute a major asset restructuring On December 24, 2015, the Company issued the "Announcement of Suspension of Trading in the Issue of Shares of Meihua Biotech Group Co., Ltd." cP4
　　1 Restructuring Framework Introduces the main trading purposes of cP4 (i) and the cP4 In order to further improve the asset quality, financial position, enhance core competitiveness and continuous operation ability of Meihua Bio, Meihua Bio intends to purchase the assets held in China by issuing shares, and the controlling shareholder stake of the company, Meng Qingshan and Meihua Bio-Related Shareholders, to transfer their shares to Xijie Upon completion of the transaction, Hijwill will become the largest shareholder of Plum Bio, directly or indirectly Upon completion of this transaction, there may be a change in the actual controller of plum bio cP4
　　The counterparty, Hi-Jie, is a joint-stock company established under Korean law and listed on the Korea Exchange, stock code: 097950 Ks cP4
　　(2) Trading Plan cP4 1 New shares issued: Meihua Bio issues shares to Hi-Jie to purchase its amino acid fermentation assets and its supporting assets in China cP4
　　2 Transfer of Old Shares: The shares of Meng Qingshan and Meihua Bio-related shareholders shall transfer part of The Shares of Meihua Bio to the other parties designated by Hij or Hija cP4
　　3 The transfer of old shares and the issuance of new shares are mutual prerequisites cP4
　　(3) The underlying assets cP4 the assets to be purchased by the company in the company's proposed shares are the amino acid fermentation assets and their supporting assets legally owned by Shijie in China, and the assets of the above-mentioned assets belong to the same manufacturing-food manufacturing industry as listed companies (the industry classification of listed companies is determined by reference to the "Industry Classification Results of Listed Companies in the 2q Quarter of 2015" published on the website of the China Association of Listed Companies) cP4
　　2 Progress of the reorganization cP4 (I) On January 11, 2016, Meng Qingshan, the controlling shareholder of the Company, and The Counterparty Xijie signed part of the non-legally binding framework agreement on restructuring, namely, the framework agreement between Xijie First Sugar Co., Ltd and Meng Qingshan on the restructuring of Meihua Biotech Group Co., Ltd cP4
　　(2) The company is, in accordance with the relevant provisions, organizing relevant intermediaries to conduct audits, assessments, legal and financial advisory services on the assets of the subject cP4
　　3 The reasons for the failure to resume trading on schedule cP4 since the suspension of trading, the company and the parties concerned have actively promoted the issue of shares to purchase assets due diligence, audit, evaluation and business negotiations and other work At present, the company is working closely to organize audit institutions, evaluation agencies to carry out audits and assessments of the assets of the target, independent financial advisers and legal advisers are carrying out due diligence work At the same time, the transaction related parties on the specific matters of this transaction plan need to continue in-depth consultation, so the Company can not as originally planned by January 24, 2016 to disclose the issuance of shares to purchase assets plan or report and re-brand cP4
　　4 Applying for a further suspension of trading time cP4 , upon application, the company's shares from January 25, 2016 onwards to continue to suspend trading for no more than 30 days cP4
　　During the suspension period, the Company and relevant parties will accelerate the process of this transaction, and will promptly fulfill the obligation of information disclosure in accordance with the progress, issue a progress announcement on the relevant matters every five trading days, pending the completion of the relevant work to convene the board of directors to consider the plan or report, timely announcement and re-listing cP4
　　The Company designated the information disclosure media as the Shanghai Securities News and the Shanghai Stock Exchange website (), the relevant announcements are based on the information published in the above-mentioned designated media, please the majority of investors pay attention to the follow-up announcement, pay attention to investment risks cP4
　　This announcement is hereby made cP4
　　The Board of Directors of Meihua Biotech Group Co., Ltd cP4 on January 22, 2016 cP4 shared to the feed